1. UNAIDS. FACT SHEET 2021 Global Hiv Statistics. End AIDS epidemic. 2021;1–3.
2. Soares R de CA, de Brito AM, Lima K, Lapa TM. Adherence to antiretroviral therapy among people living with HIV/AIDS in Northeastern Brazil: A cross-sectional study. Sao Paulo Med J. 2019;137:479–85.
3. Iacob SA, Iacob DG, Jugulete G. Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful HIV treatment-clinical points of view and practical considerations. Front Pharmacol. 2017;8.
4. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (80- ). 1997;278:1295–300.
5. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JAM, Baseler M, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997;94:13193–7.
6. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003;9:727–8.
7. Colin L, Van Lint C. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology [Internet]. 2009 [cited 2013 Mar 9];6:111. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2797771&tool=pmcentrez&rendertype=abstract
8. Sloan RD, Wainberg MA. The role of unintegrated DNA in HIV infection. Retrovirology [Internet]. BioMed Central Ltd; 2011;8:52. Available from: http://www.retrovirology.com/content/8/1/52
9. Mousseau G, Kessing CF, Fromentin R, Trautmann L, Chomont N, Valente ST. The tat inhibitor didehydro-cortistatin a prevents HIV-1 reactivation from latency. MBio. 2015;6.
10. James C Stroud, Amy Oltman, Aidong Han, Darren L. Bates LC. Structural basis of HIV-1 activation by NF-kappaB - a higher-order complex of p50:RelA bound to the HIV-1 LTR. J Mol Biol. 2009;393:98–112.
11. Cicala C, Arthos J, Censoplano N, Cruz C, Chung E, Martinelli E, et al. HIV-1 gp120 induces NFAT nuclear translocation in resting CD4+ T-cells. Virology. 2006;345:105–14.
12. Kamata H, Tsuchiya Y, Asano T. IBΒ is a positive and negative regulator of NF-B activity during inflammation. Cell Res. Nature Publishing Group; 2010; doi:10.1038/cr.2010.147.
13. Kinoshita S, Su L, Amano M, Timmerman LA, Kaneshima H, Nolan GP. The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. Immunity. 1997;6:235–44.
14. Tyagi M, Karn J. CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J. 2007;26:4985–95.
15. Coull JJ, Romerio F, Sun J-M, Volker JL, Galvin KM, Davie JR, et al. The Human Factors YY1 and LSF Repress the Human Immunodeficiency Virus Type 1 Long Terminal Repeat via Recruitment of Histone Deacetylase 1. J Virol. 2000;74:6790–9.
16. Donahue DA, Wainberg MA. Cellular and molecular mechanisms involved in the establishment of HIV-1 latency. Retrovirology [Internet]. Retrovirology; 2013;10:1. Available from: Retrovirology
17. Turner AMW, Margolis DM. Chromatin regulation and the histone code in HIV latency. Yale J Biol Med. 2017;90:229–43. Avaiable from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482300/
18. Gallastegui E, Millán-Zambrano G, Terme J-M, Chávez S, Jordan A. Chromatin reassembly factors are involved in transcriptional interference promoting HIV latency. J Virol [Internet]. 2011 [cited 2014 Mar 31];85:3187–202. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3067836&tool=pmcentrez&rendertype=abstract
19. Vansant G, Bruggemans A, Janssens J, Debyser Z. Block-and-lock strategies to cure HIV infection. Viruses. 2020;12:1–17.
20. Kessing CF, Nixon CC, Li C, Tsai P, Takata H, Mousseau G, et al. In Vivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a “Block-and-Lock” Strategy for HIV-1 Treatment. Cell Rep [Internet]. ElsevierCompany.; 2017; doi: 10.1016/j.celrep.2017.09.080.
21. Deeks SG. Shock and kill. Nature. 2012;487:439–40.
22. Jansen R, Van Embden JDA, Gaastra W, Schouls LM. Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol. 2002;43:1565–75.
23. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptative Bacterial Immunity. Science (80- ). 2012;337:816–22.
24. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science [Internet]. 2013 [cited 2014 Jul 9];339:819–23. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3795411&tool=pmcentrez&rendertype=abstract
25. Thakore PI, Black JB, Hilton IB, Gersbach CA. Editing the epigenome: technologies for programmable transcription and epigenetic modulation. Nat Methods. 2016;13:127–37.
26. Iyengar S, Farnham PJ. KAP1 protein: An enigmatic master regulator of the genome. J Biol Chem. 2011;286:26267–76.
27. Wiznerowicz M, Jakobsson J, Szulc J, Liao S, Quazzola A, Beermann F, et al. The Kruppel-associated box repressor domain can trigger de novo promoter methylation during mouse early embryogenesis. J Biol Chem [Internet]. 2007 [cited 2013 Mar 7];282:34535–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17893143
28. Pandeló José D, Bartholomeeusen K, da Cunha RD, Abreu CM, Glinski J, da Costa TBF, et al. Reactivation of latent HIV-1 by new semi-synthetic ingenol esters. Virology. Elsevier; 2014;462–463:328–39.
29. Abreu CM, Price SL, Shirk EN, Cunha RD, Pianowski LF, Clements JE, et al. Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR. PLoS One. 2014;9:e97257.
30. Elsheikh MM, Tang Y, Li D, Jiang G. Deep latency: A new insight into a functional HIV cure. EBioMedicine [Internet]. Elsevier B.V.; 2019;45:624–9. Available from: https://doi.org/10.1016/j.ebiom.2019.06.020
31. Gonzalez-Hernandez MJ, Swanson MD, Contreras-Galindo R, Cookinham S, King SR, Noel RJ, et al. Expression of Human Endogenous Retrovirus Type K (HML-2) Is Activated by the Tat Protein of HIV-1. J Virol. 2012;86:7790–805.
32. Huang Q, Chen H, Li J, Oliver M, Ma X, Byck D, et al. Epigenetic and non-epigenetic regulation of syncytin-1 expression in human placenta and cancer tissues. Cell Signal [Internet]. Elsevier B.V.; 2014; doi:10.1016/j.cellsig.2013.11.002.
33. Younas M, Psomas C, Reynes J, Corbeau P. Immune activation in the course of HIV-1 infection: Causes, phenotypes and persistence under therapy. HIV Med. 2016;17:89–105.
34. Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 2003;22:1868–77.
35. Saayman SM, Lazar DC, Scott TA, Hart JR, Takahashi M, Burnett JC, et al. Potent and targeted activation of latent HIV-1 using the CRISPR/dCas9 activator complex. Mol Ther [Internet]. Official journal of the American Society of Gene & Cell Therapy; 2016;24:488–98. Available from: http://dx.doi.org/10.1038/mt.2015.202
36. Shirakawa K, Chavez L, Hakre S, Calvanese V, Verdin E. Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol. 2013;21:277–85.
37. Divsalar DN, Simoben CV, Schonhofer C, Richard K, Sippl W, Ntie-Kang F, et al. Novel Histone Deacetylase Inhibitors and HIV-1 Latency-Reversing Agents Identified by Large-Scale Virtual Screening. Front Pharmacol. 2020;11.
38. Abreu CM, Veenhuis RT, Avalos CR, Graham S, Queen SE, Shirk EN, et al. Infectious virus persists in CD4+ T cells and macrophages in ART-suppressed SIV-infected Macaques. J Virol [Internet]. 2019; Available from: http://jvi.asm.org/lookup/doi/10.1128/JVI.00065-19
39. Veenhuis RT, Abreu CM, Shirk EN, Gama L, Clements JE. HIV replication and latency in monocytes and macrophages. Semin Immunol [Internet]. Elsevier Ltd; 2021;51:101472. Available from: https://doi.org/10.1016/j.smim.2021.101472
40. Chavez L, Calvanese V, Verdin E. HIV Latency Is Established Directly and Early in Both Resting and Activated Primary CD4 T Cells. PLoS Pathog. 2015;11:1–21.
41. Jiang C, Lian X, Gao C, Sun X, Einkauf KB, Chevalier JM, et al. Distinct viral reservoirs in individuals with spontaneous control of HIV-1. Nature. 2020;585:261–7.
42. Krasnopolsky S, Kuzmina A, Taube R. Genome-wide crispr knockout screen identifies znf304 as a silencer of HIV transcription that promotes viral latency. PLoS Pathog [Internet]. 2020;16:1–22. Available from: http://dx.doi.org/10.1371/journal.ppat.1008834
43. Nishitsuji H, Sawada L, Sugiyama R, Takaku H. ZNF10 inhibits HIV-1 LTR activity through interaction with NF-κB and Sp1 binding motifs. FEBS Lett [Internet]. Federation of European Biochemical Societies; 2015;589:2019–25. Available from: http://dx.doi.org/10.1016/j.febslet.2015.06.013
44. Ait-Ammar A, Bellefroid M, Daouad F, Martinelli V, Van Assche J, Wallet C, et al. Inhibition of HIV-1 gene transcription by KAP1 in myeloid lineage. Sci Rep [Internet]. Nature Publishing Group UK; 2021; doi:10.1038/s41598-021-82164-w.
45. Ma X, Yang T, Luo Y, Wu L, Jiang Y, Song Z, et al. TRIM28 promotes HIV-1 latency by SUMOylating CDK9 and inhibiting P-TEFb. Elife. 2019;8:1–45.
46. Cherrier T, Le Douce V, Eilebrecht S, Riclet R, Marban C, Dequiedt F, et al. CTIP2 is a negative regulator of P-TEFb. Proc Natl Acad Sci U S A. 2013;110:12655–60.
47. Yuan P, Yan J, Wang S, Guo Y, Xi X, Han S, et al. Trim28 acts as restriction factor of prototype foamy virus replication by modulating H3K9me3 marks and destabilizing the viral transactivator Tas. Retrovirology. BioMed Central; 2021;1–18. Available from: https://doi.org/10.1186/s12977-021-00584-y
48. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, et al. Repurposing CRISPR as an RNA-γuided platform for sequence-specific control of gene expression. Cell. Elsevier; 2013; doi:10.1016/j.cell.2013.02.022.
49. Jones DL, Leroy P, Unoson C, Fange D, Ćurić V, Lawson MJ, et al. Kinetics of dCas9 target search in Escherichia coli. Science (80- ). 2017; doi:10.1126/science.aah7084
50. Olson A, Basukala B, Lee S, Gagne M, Wong WW, Henderson AJ. Targeted chromatinization and repression of HIV-1 provirus transcription with repurposed CRISPR/Cas9. Viruses. 2020;12:1–12.